Sydney, Australia
Sydney, Australia

Time filter

Source Type

Russell P.,GynaePath | Russell P.,University of Sydney | Sacks G.,IVF Australia | Tremellen K.,Repromed | Gee A.,Genea
Pathology | Year: 2013

Aim: Abnormally functioning immunocompetent cells in the endometrium are thought to be responsible for at least some cases of recurrent reproductive failure [recurrent miscarriage or recurrent in vitro fertilisation (IVF) failure], but their detailed investigation has been hampered by a lack of a standardised protocol of counting such cells in study or control patients. The purpose of this study is to use a standardised protocol for the assessment of immune cells in the endometrial biopsies of a large cohort ofwomen with recurrent reproductive failure and establish relevant reference ranges. Method: In a recent study, we reported the presence and distribution of selected immune cells and macrophages in the endometria from 222 women who had a routine endometrial biopsy for investigation of recurrent miscarriage or IVF failure. Since the completion of that study, a further 1767 cases have been examined, using the same assessment parameters of the earlier study. Results: This updated analysis of 1989 endometrial biopsies provides reference ranges for CD8 +, CD163+, CD56+ and CD57+ cells for individual 'days' of a normalised menstrual cycle. CD8+ T-cells displayed a modest (50%) increase in numbers in the luteal phase and periglandular aggregation was a useful indicator of a subtle focal endometritis, possibly of infective origin, and generally not identified in H&E sections. A rapid accumulation of CD163+ macrophages occurs in the superficial stroma after day 22 of the cycle, while a significant number of cases displayed single or clustered macrophages within glandular lumens of the superficial endometrium in luteal phase, especially after day 20 of the cycle. The significance of this change is unclear but may relate to a macrophage response to abnormal glandular secretion or to bleeding occurring at the time of ovulation. CD56+ uterine natural killer (uNK) cells show such a dramatic rise in both absolute numbers and percentage of stromal cells from day 22 of the standardised 28 day cycle that this needs to be taken into account in all clinical studies or individual assessments of endometrial biopsies. CD57+ NK cells are seen in small numbers in most cases and cell counts of greater than 10 per mm2 are regarded as abnormal. Conclusions: This large database provides a daily range which is the most accurate survey yet of uNK cell numbers. Co-location of CD8+ T-cells and CD56+ uNK cells in perviascular aggregates has been demonstrated. © 2013 Royal College of Pathologists of Australasia.


Merck, ein führendes Wissenschafts- und Technologieunternehmen, hat heute die Einführung von zwei neuen, innovativen Fertilitätstechnologien, Gidget™ und Geri™+, bekannt gegeben. Damit erweitert das Unternehmen sein innovatives Portfolio zur Unterstützung aller Schritte, die in IVF-(in-vitro-Fertilisation)-Laboren im Rahmen der assistierten Reproduktionstechnologie (ART) durchgeführt werden. Hierbei leistet Technologie einen entscheidenden Beitrag für den Behandlungserfolg. Gidget™ ist als benutzerfreundliches Dokumentations- und Trackingystem konzipiert, es soll das Risiko von Fehlern reduzieren und die Arbeitsabläufe im Labor verbessern. Geri™+ erlaubt eine Verknüpfung des Embryoneninkubators Geri™ mit dem innovativen Eeva®-Algorithmus. Beide neuen Produkte untermauern die Healthcare-Strategie von Merck, mittels Best-in-Class-Produkten Patienten mit Innovationen zu helfen. "Als weltweit führendes Unternehmen im Bereich Fertilitätsbehandlungen konzentriert sich Merck weiter auf Innovationen, um Kliniken individualisierte Behandlungsentscheidungen für und mit ihren Patientinnen zu ermöglichen", sagte Rehan Verjee, Chief Marketing and Strategy Officer im Biopharma-Geschäft von Merck. "Sowohl Gidget als auch Geri+ bieten Embryologen mehr Optionen, um Frauen und Paaren mit Kinderwunsch bestmögliche Behandlungslösungen anzubieten, zum Beispiel durch erhöhte Sicherheit und Gewissheit für die Patientinnen und durch personalisiertes Workflow-Management und Patienten-Tracking." Gidget™ und Geri™+ stammen aus dem Entwicklungskooperation ARTinnovations, die Merck zusammen mit Genea Biomedx Propriety Ltd., Sydney, Australien, gegründet hat. ARTinnovations dient als Inkubator für Ideen und Innovationen für Fertilitätsbehandlungen und -technologien. In ihm ergänzen sich Engagement und Know-how beider Partner mit dem Ziel, Ideen für langfristig bessere Behandlungsergebnisse für die Patienten in Produkte umzusetzen. Durch die Integration von Hell- und Dunkelfeldmikroskopie lässt sich der Geri™+-Inkubator nun in Kombination mit der Eeva® Software und Geri Assess einsetzen. Geri™+ wird damit zu einem multifunktionalen Inkubator, der Embryologen eine Vielfalt von Möglichkeiten rund um die Embryonenanalyse eröffnet. Er vereint die Vorteile der störungsfreien Inkubation mit den hohen Kontroll- und Sicherheitsstandards des Geri™-Inkubators und der Eeva® Software. Dabei handelt es sich um, dem ersten automatisierten Algorithmus, für den klinisch belegt wurde, dass er die Beurteilung der Embryonenentwicklung verbessert.1,2,3 Gidget™ ist ein tragbares Gerät für das IVF-Labor, mit dem sich Embryologen ganz auf ihre wissenschaftliche Arbeit konzentrieren können, da das Risiko einer Fehlzuordnung ausgeschlossen wird. Es bietet besondere Tracking- und Workflow-Funktionalitäten wie elektronische Dokumentation, Verwaltung der Arbeitsabläufe im Labor und Unterstützung bei Rückverfolgbarkeit und der Berichterstattung im Rahmen von Audits. Beide Produkte sind ab sofort in Europa und Kanada verfügbar. Gidget™ wird zudem in den USA und Japan sowie bald in weiteren Regionen eingeführt. Gidget™ wurde als benutzerfreundliches, tragbares Gerät für die Identifizierung und Nachverfolgung von Proben im Rahmen von ART-Prozessen konzipiert. Mit Gidget™ werden Schalen, Röhrchen und andere Verbrauchsgüter gescannt, in denen Patientenmaterialien aufbewahrt und verarbeitet werden. So lassen sich Zuordnungsfehler verhindern. Darüber hinaus bietet Gidget™ jedoch noch weitere Funktionen und Vorteile für das Labor, abgesehen vom reinen Dokumentationssystem. So ermöglicht es intelligente und persönlich abgestimmte Unterstützung von ART-Prozessen, was klinisches Workflow-Management und Patienten-Tracking betrifft. Geri™+ ist ein innovativer, multifunktionaler Inkubator mit individuell regelbaren Inkubationskammern für jede Patientin. In das Gerät ist ein Kamerasystem integriert, das Bilder von den Embryos während ihrer Entwicklung in Echtzeit aufzeichnet. Das Gerät ist nun mit den Analysefunktionen der Eeva® Software kombinierbar. Mit dem Ziel, jedem Embryo beste Entwicklungsmöglichkeiten zu bieten, wurde Geri™+ dafür konzipiert, durch höchste Kontroll- und Sicherheitsstandards Störeinflüsse auf die Embryonen zu minimieren. Die Entwicklungszentrum ARTinnovations dient als Inkubator für Ideen und Innovationen für Fertilitätsbehandlungen und -technologien. Durch die Kooperation zwischen Genea Biomedx und Merck bietet ARTinnovations Unterstützung und Know-how bei der Entwicklung von Ideen für langfristig bessere Behandlungsergebnisse für die Patienten zu etablieren. Aufbauend auf seiner langen Tradition im Bereich Fertilitätsbehandlungen will Merck mit dem ARTinnovations-Entwicklungszentrum zusammen mit dem Partner eine innovative Pipeline an Fertilitätstechnologien und -dienstleistungen entwickeln, um Patientinnen, die sich einer ART-Behandlung unterziehen, zu unterstützen und Ärzten objektive Informationen für wichtige Behandlungsentscheidungen zu liefern. Sämtliche Pressemeldungen von Merck werden zeitgleich mit der Publikation im Internet auch per E-Mail versendet. Nutzen Sie die Web-Adresse http://www.merck.de/newsabo, um sich online zu registrieren, die getroffene Auswahl zu ändern oder den Service wieder zu kündigen. Merck ist ein führendes Wissenschafts- und Technologieunternehmen in den Bereichen Healthcare, Life Science und Performance Materials. Rund 50.000 Mitarbeiter arbeiten daran, Technologien weiterzuentwickeln, die das Leben bereichern - von biopharmazeutischen Therapien zur Behandlung von Krebs oder Multipler Sklerose über wegweisende Systeme für die wissenschaftliche Forschung und Produktion bis hin zu Flüssigkristallen für Smartphones oder LCD-Fernseher. 2015 erwirtschaftete Merck in 66 Ländern einen Umsatz von 12,85 Milliarden Euro. Gegründet 1668 ist Merck das älteste pharmazeutisch-chemische Unternehmen der Welt. Die Gründerfamilie ist bis heute Mehrheitseigentümerin des börsennotierten Konzerns. Merck mit Sitz in Darmstadt besitzt die globalen Rechte am Namen und der Marke Merck. Einzige Ausnahmen sind die USA und Kanada, wo das Unternehmen als EMD Serono, MilliporeSigma und EMD Performance Materials auftritt.


MarketStudyReport.com adds “Assisted Reproductive Technology (ART) Market Size by Procedure (Fresh Donor, Fresh Nondonor, Frozen Donor, Frozen Nondonor, Egg/Embryo bank), Industry Analysis Report, Regional Outlook (U.S, Canada, UK, France, Germany, Italy, Spain, China, India, Japan, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 ? 2023” new report to its research database. The report spread across 73 pages with table and figures in it. Assisted Reproductive Technology (ART) Market size was $22.31 billion for 2015 and is predicted to be evaluated at $31.41 billion by end of forecast period registering CAGR of 4.4%. ART is a modern technique used to treat infertility. The procedures included in it are gamete intrafallopian transfer (GIFT), in vitro fertilization (IVF), zygote intrafallopian transfer (ZIFT) and intracytoplasmic sperm injection (ICSI). In vitro fertilization (IVF) is the leading method in which eggs and sperms are combined in laboratory and fertilized eggs are transferred into uterus of woman. IVF process includes stimulation of ovaries, egg recovery, fertilization, embryo culture and transfer of embryo. GIFT (Gamete intrafallopian transfer)is a method in which gametes are transferred into fallopian tube of woman and fertilization takes place in fallopian tubes. The method is performed only if fallopian tubes are functioning normally. In ZIFT (zygote intrafallopian transfer) fertilization occurs in laboratory instead of fallopian tube and fertilized eggs are moved to fallopian tube instead of uterus. ICSI (intracytoplasmic sperm injection) is a technique in which sperm is directly inserted into matured egg. In U.S ICSI methods very popular and leads ART methods. Procedure Overview The industry is segmented into fresh donor segment and frozen non-donor segment. Fresh donor segment exceeded $1.3 billion revenue mark for 2015 and is predicted to register more than 5% CAGR during forecast timeframe. The proportion of donor eggs used in assisted reproductive technology cycles grows with age. As per CDC (Centers for Disease Control and Prevention), the kind of ART (assisted reproductive technology) cycles differ with woman’s age. These cycles where woman uses own eggs is mostly dominated by young women. For instance, 97.01% of women below 35 years of age used their own eggs for fertilization. Frozen non-donor segment is predicted to register CAGR of 5.8% during forecast timeframe. Assisted Reproductive Technology (ART) Market Size Regional Overview APAC assisted reproductive technology market share contributed more than 19% of total revenue and is predicted to register CAGR of 6.1% during forecast timeframe. Rapid growth in healthcare sector in nations like Japan, China and India is predicted to promote industry expansion during forecast period. North America assisted reproductive technology market size was evaluated at more than $9 billion for 2015 and is anticipated to be evaluated at greater than $11 billion by end of 2023. It is predicted to register CAGR of about 2.7% during forecast timeframe. Rise in infertility owing to fatness and demographical changes have fueled expansion of North America assisted reproductive technology industry. Europe assisted reproductive technology market contributed more than 22.51% of the total revenue share and is predicted to register a CAGR of 2.7% during forecast timeframe. Competitive Trends Key industry players profiled in the report include Vitro Life, Research Instruments,Thermo Fisher Scientific Incorporation, Irvine scientific, Genea Limited,Research Instruments, IVFtech ApS, Origio a/s, Esco Micro Private Limited, Cook Medicaland Smiths Medical. To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


Koch J.,IVF Australia | Rowan K.,Genea | Rombauts L.,Monash University | Yazdani A.,University of Queensland | And 2 more authors.
Australian and New Zealand Journal of Obstetrics and Gynaecology | Year: 2012

Endometriosis is common in women with infertility but its management is controversial and varied. This article summarises the consensus developed by a group of Australasian subspecialists in reproductive endocrinology and infertility (the Australasian CREI Consensus Expert Panel on Trial evidence group) on the evidence concerning the management of endometriosis in infertility. Endometriosis impairs fertility by causing a local inflammatory state, inducing progesterone resistance, impairing oocyte release and reducing sperm and embryo transport. Medical treatments have a limited role, whereas surgical and assisted reproductive treatments improve pregnancy rates. The role of surgery for deep infiltrative endometriosis and repeat surgery requires further evaluation and there is insufficient evidence for the use of anti-adhesives to improve fertility. Intrauterine insemination (IUI) and in vitro fertilisation (IVF) improve pregnancy rates but women with endometriosis have lower pregnancy rates than those with other causes of infertility. The decision about whether to operate or pursue assisted reproduction will depend on a variety of factors such as the patient's symptoms, the presence of complex masses on ultrasound, ovarian reserve and ovarian access for IVF, risk of surgery and cost. Some women with infertility and endometriosis may benefit from a combination of assisted reproduction and surgery. © 2012 The Authors ANZJOG © 2012 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.


News Article | November 17, 2016
Site: en.prnasia.com

Not intended for U.S. based media Merck, a leading science and technology company, today announced the launch of the two new innovative fertility technologies Gidget™ and Geri™+ to extend its innovative portfolio to support all steps performed by fertility laboratories during assisted reproductive treatment (ART), where technologies play a vital role for treatment success. Gidget™ is designed as an easy-to-use witnessing and tracking system to reduce the potential for error and improve lab workflows, and Geri™+ is the basis to combine the Geri™ embryo incubator and the innovative Eeva® algorithm. Both new products underline Merck's healthcare strategy to provide innovation to patients / customers through best-in-class products. "As the worldwide leader in fertility treatments, Merck continues to focus on innovation, in order to enable clinics to make individualized treatment decisions with and for their patients," said Rehan Verjee, Chief Marketing and Strategy Officer at the biopharma business of Merck. "Both Gidget™ and Geri™+ increase embryologists' options to provide the best possible treatment solutions for women and couples wanting to have a baby, such as offering greater safety and assurance for IVF patients and enabling a personalized workflow management and patient tracking." Gidget™ and Geri™+ stem from the ARTinnovations development hub, which Merck formed in collaboration with Genea Biomedx Propriety Ltd., Sydney, Australia. ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. It combines the commitment and know-how of both partners to develop ideas that can take root and grow into better outcomes for patients. Integrating bright- and dark-field imaging, the Geri™+ incubator now allows for combination with the Eeva® software and any Geri Assess version. Geri+ becomes a multifunctional incubator, which gives embryologists a multitude of possibilities around embryo analytics. It brings together the benefits of undisturbed incubation, while complying with the high control and safety standards of the GeriTM incubator and the analytics of the Eeva® software, the first automated algorithm clinically shown to improve embryo assessment.[1],[2],[3] Gidget™ is a hand-held device for the IVF laboratory that lets the embryologist focus on the science by eliminating any chance of mismatching, and includes unique tracking and workflow features. It provides electronic witnessing, lab workflow management and support for traceability and audit reporting. Both products will be available immediately in Europe and Canada, with Gidget™ also launching in the US, Japan and additional regions set to follow soon. Gidget™ is designed as easy-to-use hand-held device to aid sample identification and tracking during ART procedures. Gidget™ is used to scan dishes, tubes and other consumables used to maintain and process patient material to eliminate mismatching from occurring. However, Gidget™ provides further functionalities and benefits for the lab than a pure witnessing system, enabling a personalized intelligent ART assistance for clinical workflow management and patient tracking. Geri™+ is an innovative multifunctional incubator with individually controlled incubation chambers per patient and a camera to real time monitor the developing embryos, now combinable with the analytics of the Eeva® software. To give each embryo the best chance of development, Geri™+ is designed to provide undisturbed incubation environment with the highest control and safety standards. The development hub ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. A collaboration between Genea Biomedx and Merck, ARTinnovations provides the support and know-how to develop ideas so that they take root and grow into better outcomes for patients. Building on its strong heritage in fertility treatment, Merck aims to jointly develop an innovative pipeline of fertility technologies and services through the ARTinnovations hub, to help support patients undergoing ART and provide healthcare professionals with objective information to make important treatment decisions. All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service. Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of EUR 12.85 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


PubMed | University of Auckland, Genea, Assisted Conception Australia, Monash IVF and University of New South Wales
Type: Consensus Development Conference | Journal: The Australian & New Zealand journal of obstetrics & gynaecology | Year: 2016

Ovarian hyperstimulation syndrome is an important condition with considerable morbidity and a small risk of mortality, which most commonly results as an iatrogenic condition following follicular stimulation of the ovaries.To produce evidence-based and consensus statements on the prevention and detection of ovarian hyperstimulation syndrome (OHSS).The CREI Consensus Group met in 2008 and identified issues for inclusion and review. Review of the available evidence was conducted and consensus statements prepared. Areas of dissent of expert opinion and for further research were noted.The group considered that there is a need for standardisation of the definition and classification of the clinical syndrome of OHSS to allow further conclusive research. Interventions with evidence of effect in reducing OHSS include the use of metformin in women with PCOS, use of GnRH antagonist rather than GnRH agonist and use of GnRH agonist triggers in GnRH antagonist stimulation cycles. The consensus view was that reducing the dose of FSH, freezing all embryos and transferring a single embryo were appropriate interventions to reduce OHSS. Agreement could not be reached on coasting, the lowest number of oocytes to consider freezing all embryos and management after cancellation of oocyte collection.OHSS is a serious condition for which there are a number of proven preventative strategies. OHSS is an area requiring ongoing research and development of a universally agreed definition will allow development of optimal prevention strategies and facilitate improved early detection of women at risk.


Traversa M.V.,Genea | Marshall J.,Genea | McArthur S.,Genea | Leigh D.,Genea
Reproductive Biology | Year: 2011

Comparative genomic hybridization (CGH) is an indirect DNA-based test which allows for the accurate analysis of aneuploidy involving any of the 24 types of chromosomes present (22 autosomes and the X and Y sex chromosomes). Traditionally, embryos have been screened using fluorescence in situ hybridization (FISH) - a technique that was limited in the number of chromosomes able to be identified in any one sample. Early CGH reports on aneuploidy in preimplantation embryos showed that any of the 24 chromosomes could be involved and so FISH methods were going to be ineffective in screening out abnormal embryos. Our results from routine clinical application of array CGH in preimplantation genetic diagnosis (PGD) patients confirm previous reports on patterns of chromosomal contribution to aneuploidy. The pregnancy outcomes following embryo transfer also indicate that despite the requirement to freeze embryos, rates are encouraging, and successful ongoing pregnancies can be achieved. © 2011 by the Society for Biology of Reproduction.


Bonifacio M.,Genea | Bradley C.K.,Genea | Karia S.,Genea | Livingstone M.,Genea | And 2 more authors.
Journal of Assisted Reproduction and Genetics | Year: 2015

Purpose: Anti-Müllerian hormone (AMH) is used as a marker for ovarian reserve. Since 2011, the standard test for AMH has been the Beckman Coulter Generation (Gen) II assay. However, in July 2013, the protocol was revised due to falsely low readings. The aim of this study was to compare AMH levels measured with the original and revised Gen II assay and to establish a fertile female reference range for the revised protocol. Methods: Serum AMH levels were measured for 492 natural conception first trimester pregnant women using the original and revised Gen II assay. Results: The original protocol significantly underestimated AMH levels compared with the revised protocol (p < 0.001), the median being 8.4 and 14.2 pmol/L, respectively. In all samples with detectable AMH levels, the revised protocol yielded a higher concentration compared with the original protocol, the magnitude shift ranging from 3.4 to 283.3 % (median 68.0 %). AMH levels measured with the revised protocol were collated to generate an age-specific reference range, with median levels peaking at 27 years then declining with advancing age. The median AMH concentration for ages 20–24 was 17.3 pmol/L, ages 25–29 was 20.5 pmol/L, ages 30–34 was 17.8 pmol/L, ages 35–39 was 10.8 pmol/L, and ages 40–44 was 6.1 pmol/L. Conclusions: Our study demonstrated that the original Gen II assay significantly underestimated AMH levels, suggesting caution is required when interpreting literature and testing results achieved with this assay. We also established the revised Gen II assay reference range for AMH in women with unassisted proven fertility. © 2015, Springer Science+Business Media New York.


Roy T.K.,Genea | Bradley C.K.,Genea | Bowman M.C.,Genea | McArthur S.J.,Genea
Fertility and Sterility | Year: 2014

Objective To compare pregnancy and neonatal outcomes after fresh and vitrified-warmed single-blastocyst transfers. Design Retrospective study. Setting Private in vitro fertilization (IVF) clinic. Patient(s) 1,209 infertile patients who underwent a total of 1,157 fresh and 645 vitrified-warmed embryo transfers. Intervention(s) Day-5 single-blastocyst transfers using fresh or vitrified-warmed (Cryotop method) grade I and grade II embryos. Main Outcome Measure(s) Fetal heart pregnancy rate, live-birth rate, gestational age, and live-birth weight. Result(s) The overall blastocyst thaw survival rate was 94.4% and was not significantly different between blastocyst grades or developmental stages. Similar clinical outcomes were achieved for fresh and vitrified-warmed blastocyst transfers; for example, grade I blastocysts had a live-birth rate of 52.8% versus 55.3%, respectively, and grade II blastocysts had a rate of 34.9% versus 30.4%, respectively. Significantly improved neonatal outcomes were evident for vitrified-warmed blastocyst transfers for gestational age, being on average 0.3 weeks longer, and for live-birth weight with babies born on average 145 g heavier (3,296 g versus 3,441 g for fresh and vitrified-warmed groups, respectively), as compared with fresh transfers. Conclusion(s) Embryo transfer of vitrified-warmed blastocysts yields equivalent live-birth rates and improved neonatal outcomes compared with fresh transfers. Copyright © 2014 American Society for Reproductive Medicine, Published by Elsevier Inc.


News Article | November 17, 2016
Site: www.prnewswire.co.uk

Not intended for U.S. based media Merck, a leading science and technology company, today announced the launch of the two new innovative fertility technologies Gidget™ and Geri™+ to extend its innovative portfolio to support all steps performed by fertility laboratories during assisted reproductive treatment (ART), where technologies play a vital role for treatment success. Gidget™ is designed as an easy-to-use witnessing and tracking system to reduce the potential for error and improve lab workflows, and Geri™+ is the basis to combine the Geri™ embryo incubator and the innovative Eeva® algorithm. Both new products underline Merck's healthcare strategy to provide innovation to patients / customers through best-in-class products. "As the worldwide leader in fertility treatments, Merck continues to focus on innovation, in order to enable clinics to make individualized treatment decisions with and for their patients," said Rehan Verjee, Chief Marketing and Strategy Officer at the biopharma business of Merck. "Both Gidget™ and Geri™+ increase embryologists' options to provide the best possible treatment solutions for women and couples wanting to have a baby, such as offering greater safety and assurance for IVF patients and enabling a personalized workflow management and patient tracking." Gidget™ and Geri™+ stem from the ARTinnovations development hub, which Merck formed in collaboration with Genea Biomedx Propriety Ltd., Sydney, Australia. ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. It combines the commitment and know-how of both partners to develop ideas that can take root and grow into better outcomes for patients. Integrating bright- and dark-field imaging, the Geri™+ incubator now allows for combination with the Eeva® software and any Geri Assess version. Geri+ becomes a multifunctional incubator, which gives embryologists a multitude of possibilities around embryo analytics. It brings together the benefits of undisturbed incubation, while complying with the high control and safety standards of the GeriTM incubator and the analytics of the Eeva® software, the first automated algorithm clinically shown to improve embryo assessment.[1],[2],[3] Gidget™ is a hand-held device for the IVF laboratory that lets the embryologist focus on the science by eliminating any chance of mismatching, and includes unique tracking and workflow features. It provides electronic witnessing, lab workflow management and support for traceability and audit reporting. Both products will be available immediately in Europe and Canada, with Gidget™ also launching in the US, Japan and additional regions set to follow soon. Gidget™ is designed as easy-to-use hand-held device to aid sample identification and tracking during ART procedures. Gidget™ is used to scan dishes, tubes and other consumables used to maintain and process patient material to eliminate mismatching from occurring. However, Gidget™ provides further functionalities and benefits for the lab than a pure witnessing system, enabling a personalized intelligent ART assistance for clinical workflow management and patient tracking. Geri™+ is an innovative multifunctional incubator with individually controlled incubation chambers per patient and a camera to real time monitor the developing embryos, now combinable with the analytics of the Eeva® software. To give each embryo the best chance of development, Geri™+ is designed to provide undisturbed incubation environment with the highest control and safety standards. The development hub ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. A collaboration between Genea Biomedx and Merck, ARTinnovations provides the support and know-how to develop ideas so that they take root and grow into better outcomes for patients. Building on its strong heritage in fertility treatment, Merck aims to jointly develop an innovative pipeline of fertility technologies and services through the ARTinnovations hub, to help support patients undergoing ART and provide healthcare professionals with objective information to make important treatment decisions. All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service. Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Loading Genea collaborators
Loading Genea collaborators